J Korean Orthop Assoc.  2012 Apr;47(2):156-159. 10.4055/jkoa.2012.47.2.156.

A Medication for Newly Diagnosed Rheumatoid Arthritis in Patient with Lactose Intolerance

• Son JH
• Lee GW

• KMID: 2185393
• DOI: http://doi.org/10.4055/jkoa.2012.47.2.156

Abstract

The side effects of rheumatoid arthritis (RA) medication, such as irritation and ulceration of the gastrointestinal mucosa, have been observed and many patients find it difficult to swallow tablets and hard gelatin capsules. This results in a high incidence of noncompliance and ineffective therapy towards treating RA. Fast-dissolving and fast-dispersing drug delivery systems may offer a solution to these problems, and as a result, fast disintegrating tablets are gaining prominence as a new drug-delivery system; one such system is the binding of the active ingredient with lactose. There have been no reports on the rate of lactose intolerance against medication in patients with newly diagnosed RA, because lactose intolerance has not been associated with particular problems with most existing RA therapies. We encounterd a 56-year-old lactose intolerant female patient who had severe diarrhea after receiving drugs to treat her newly diagnosed RA.

Keyword

lactose intolerance; rheumatoid arthritis

MeSH Terms

Arthritis, Rheumatoid
Capsules
Diarrhea
Drug Delivery Systems
Female
Gelatin
Humans
Incidence
Lactose
Lactose Intolerance
Middle Aged
Mucous Membrane
Tablets
Ulcer
Capsules
Gelatin
Lactose
Tablets

Figure

• 

  Figure 1 Anteroposterior radiograph shows a mild narrowing of the medial joint with minimal osteophytes.

• 

  Figure 2 The arthroscopic finding shows generalized villous synovitis (A) and a torn medial meniscus (B).

Reference

1. Hur NW, Choi CB, Uhm WS, Bae SC. The prevalence and trend of arthritis in Korea: results from Korea National Health and Nutritional Examination Surveys. J Korean Rheum Assoc. 2008. 15:11–26.

2. Deighton C, O'Mahony R, Tosh J, Turner C, Rudolf M. Guideline Development Group. Management of rheumatoid arthritis: summary of NICE guidance. BMJ. 2009. 338:b702.

3. Roy SD, Manoukian E. Permeability of ketorolac acid and its ester analogs (prodrug) through human cadaver skin. J Pharm Sci. 1994. 83:1548–1553.

4. Heyman MB. Committee on Nutrition. Lactose intolerance in infants, children, and adolescents. Pediatrics. 2006. 118:1279–1286.

5. Vesa TH, Marteau P, Korpela R. Lactose intolerance. J Am Coll Nutr. 2000. 19:165S–175S.

6. Seager H. Drug-delivery products and the Zydis fast-dissolving dosage form. J Pharm Pharmacol. 1998. 50:375–382.

7. Biradar SS, Bhagavati ST, Kuppasad IJ. Fast dissolving drug delivery systems: a brief overview. Internat J Pharmacol. 2006. 4.

8. Battu SK, Repka MA, Majumdar S, Madhusudan RY. Formulation and evaluation of rapidly disintegrating fenoverine tablets: effect of superdisintegrants. Drug Dev Ind Pharm. 2007. 33:1225–1232.